JP2023531968A5 - - Google Patents
Info
- Publication number
- JP2023531968A5 JP2023531968A5 JP2022579724A JP2022579724A JP2023531968A5 JP 2023531968 A5 JP2023531968 A5 JP 2023531968A5 JP 2022579724 A JP2022579724 A JP 2022579724A JP 2022579724 A JP2022579724 A JP 2022579724A JP 2023531968 A5 JP2023531968 A5 JP 2023531968A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- bet
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047126P | 2020-07-01 | 2020-07-01 | |
| US63/047,126 | 2020-07-01 | ||
| US202063129253P | 2020-12-22 | 2020-12-22 | |
| US63/129,253 | 2020-12-22 | ||
| PCT/US2021/039945 WO2022006305A1 (en) | 2020-07-01 | 2021-06-30 | Methods of treating allergy using anti-bet v 1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531968A JP2023531968A (ja) | 2023-07-26 |
| JP2023531968A5 true JP2023531968A5 (enExample) | 2024-07-08 |
Family
ID=77168400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579724A Pending JP2023531968A (ja) | 2020-07-01 | 2021-06-30 | 抗ｂｅｔ ｖ １抗体を使用してアレルギーを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11897945B2 (enExample) |
| EP (1) | EP4175986A1 (enExample) |
| JP (1) | JP2023531968A (enExample) |
| KR (1) | KR20230030573A (enExample) |
| CN (1) | CN115698059A (enExample) |
| AU (1) | AU2021300129A1 (enExample) |
| BR (1) | BR112022026279A2 (enExample) |
| CA (1) | CA3177918A1 (enExample) |
| CL (1) | CL2022003744A1 (enExample) |
| IL (1) | IL299207A (enExample) |
| MX (1) | MX2022015677A (enExample) |
| WO (1) | WO2022006305A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL270894B2 (en) * | 2017-06-01 | 2023-04-01 | Regeneron Pharma | Human antibodies to bet v 1 and methods of using them |
| AU2021300129A1 (en) | 2020-07-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-Bet v 1 antibodies |
| WO2024251358A1 (en) * | 2023-06-07 | 2024-12-12 | Mabylon Ag | Anti-allergen antibodies and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5411594A (en) | 1992-10-27 | 1994-05-24 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order |
| WO1994014475A1 (en) | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1219299B2 (en) | 2000-12-28 | 2010-11-10 | Biomay Ag | Allergy vaccines and their preparation |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| ITMI20052517A1 (it) | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AT503297B1 (de) | 2006-05-18 | 2007-09-15 | Biomay Ag | Allergen-spezifische antikörper |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| IL270894B2 (en) | 2017-06-01 | 2023-04-01 | Regeneron Pharma | Human antibodies to bet v 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| AU2021300129A1 (en) | 2020-07-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-Bet v 1 antibodies |
| US20250263471A1 (en) | 2024-01-30 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
-
2021
- 2021-06-30 AU AU2021300129A patent/AU2021300129A1/en active Pending
- 2021-06-30 MX MX2022015677A patent/MX2022015677A/es unknown
- 2021-06-30 IL IL299207A patent/IL299207A/en unknown
- 2021-06-30 WO PCT/US2021/039945 patent/WO2022006305A1/en not_active Ceased
- 2021-06-30 CA CA3177918A patent/CA3177918A1/en active Pending
- 2021-06-30 BR BR112022026279A patent/BR112022026279A2/pt unknown
- 2021-06-30 CN CN202180043390.9A patent/CN115698059A/zh active Pending
- 2021-06-30 EP EP21749400.4A patent/EP4175986A1/en active Pending
- 2021-06-30 US US17/364,299 patent/US11897945B2/en active Active
- 2021-06-30 KR KR1020227043651A patent/KR20230030573A/ko active Pending
- 2021-06-30 JP JP2022579724A patent/JP2023531968A/ja active Pending
-
2022
- 2022-12-23 CL CL2022003744A patent/CL2022003744A1/es unknown
-
2023
- 2023-12-19 US US18/545,795 patent/US12583914B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021112207A5 (enExample) | ||
| JP2020523004A5 (enExample) | ||
| JP2022543612A5 (enExample) | ||
| JP2023531968A5 (enExample) | ||
| TWI859164B (zh) | 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法 | |
| JP2022543815A5 (enExample) | ||
| US8815245B2 (en) | Method of treating viral diseases | |
| JP2024531151A5 (enExample) | ||
| JP2024174962A5 (enExample) | ||
| JP2024502471A5 (enExample) | ||
| Arroyave et al. | Plasma complement changes during bronchospasm provoked in asthmatic patients | |
| JP2023520676A5 (enExample) | ||
| JP2023551559A5 (enExample) | ||
| JP2005508338A (ja) | 免疫性疾患を処置するためのガンマグロブリンの使用 | |
| Nakagawa et al. | Changes of house dust mite-specific IgE, IgG and IgG subclass antibodies during immunotherapy in patients with perennial rhinitis | |
| Ebner et al. | Booster immunotherapy (BIT) | |
| JP2024532263A5 (enExample) | ||
| IL299207A (en) | Methods of allergy treatment using anti-BET V 1 antibodies | |
| JP2025501239A5 (enExample) | ||
| JP2024532438A5 (enExample) | ||
| JP2019508458A5 (enExample) | ||
| Gold | Neurohumoral interactions in airways | |
| RU2191601C1 (ru) | Лекарственное средство и способ лечения эректильных дисфункций | |
| HOWARD et al. | Effects of pituitary adrenocorticotropic hormone (ACTH) on the hypersensitive state | |
| JP2023531722A5 (enExample) |